Back to all studies
💉
Phase 2
Diabetes
in-person

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic K…

Sponsored by Regeneron Pharmaceuticals

Compensation

Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.

Duration

3 months

Location

Nationwide

About this study

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Who can participate

  • • Adults aged 18–80
  • • All genders welcome
  • • Diagnosed with or experiencing diabetic kidney disease (dkd)
  • • Able to attend in-person clinic visits

What's included

  • • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.

Source: ClinicalTrials.gov record NCT07271186

Ready to Find a Research Study?

Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.